Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin to Reduce Cardiac Toxicity in Breast Cancer Patients
NCT02472353Phase 2Terminated
- Sponsor
- Avera McKennan Hospital & University Health Center
- Start
- Jul 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Cardiotoxicity comparing Standard of Care with Metformin + Standard of Care (2 arms). Primary endpoint: Number of Participants With Less Than or Equal to 5% Decrease in Left Ventricle Ejection Fraction (LVEF) on Echocardiogram at 1 year. Started Jul 2014; status: terminated.
02
Drugs
metformin
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT02472353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472353.